Evidence map›Paper›PMID 26352647›Full record

ArticleNature biotechnology2015

De novo sequencing and variant calling with nanopores using PoreSeq.

Tamas Szalay, Jene A Golovchenko

Abstract read
In one paragraph

Article in Nature biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Review
  2. Article
  3. Small Open Reading Frame-Encoded Micro-Peptides: An Emerging Protein World.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. InnovativeFrontiers in genetics · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Next-Generation Sequencing in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2019
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tamas SzalaySchool of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.ORCID http://orcid.org/0000-0002-6539-7497
Jene A GolovchenkoSchool of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.

Funding

Electronic Sequencing in NanoporesR01HG003703 · NHGRI · HARVARD UNIVERSITY · PI BRANTON, DANIEL NONE, GOLOVCHENKO, JENE A · 2005 to 2014
$16.1M
NHGRI NIH HHS R01 HG003703NHGRI NIH HHS R01HG003703
6 · The paper itself

Abstract

The accuracy of sequencing single DNA molecules with nanopores is continually improving, but de novo genome sequencing and assembly using only nanopore data remain challenging. Here we describe PoreSeq, an algorithm that identifies and corrects errors in nanopore sequencing data and improves the accuracy of de novo genome assembly with increasing coverage depth. The approach relies on modeling the possible sources of uncertainty that occur as DNA transits through the nanopore and finds the sequence that best explains multiple reads of the same region. PoreSeq increases nanopore sequencing read accuracy of M13 bacteriophage DNA from 85% to 99% at 100× coverage. We also use the algorithm to assemble Escherichia coli with 30× coverage and the λ genome at a range of coverages from 3× to 50×. Additionally, we classify sequence variants at an order of magnitude lower coverage than is possible with existing methods.

Indexed as

AlgorithmsBase SequenceChromosome MappingDNA, ViralGenetic VariationMolecular Sequence DataNanoporesReproducibility of ResultsSensitivity and SpecificitySequence Analysis, DNADNA, Viral

Identifiers

PMID26352647
PMCPMC4877053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.